Grifols (NASDAQ:GRFS) Posts Earnings Results, Beats Expectations By $0.14 EPS

Grifols (NASDAQ:GRFS) issued its quarterly earnings results on Monday. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.14, FiscalAI reports. Grifols had a net margin of 5.54% and a return on equity of 6.21%.

Grifols Trading Up 4.6%

Shares of NASDAQ GRFS traded up $0.38 during mid-day trading on Monday, hitting $8.47. 849,806 shares of the company traded hands, compared to its average volume of 641,149. Grifols has a 1 year low of $6.96 and a 1 year high of $9.90. The stock has a market capitalization of $5.77 billion, a price-to-earnings ratio of 44.56, a PEG ratio of 0.29 and a beta of 0.75. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The business has a 50 day moving average of $7.59 and a two-hundred day moving average of $8.01.

Analyst Upgrades and Downgrades

GRFS has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday, October 26th. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $9.00.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.